Esperion Therapeutics Inc Total Assets
Esperion Therapeutics Inc total assets. Based on the latest financial reports, Esperion Therapeutics Inc (ESPR) holds total assets worth $364.02 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Esperion Therapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Esperion Therapeutics Inc (1999–2024)
Total assets of Esperion Therapeutics Inc from 1999 to 2024. This chart illustrates how Esperion Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See ESPR stock price and chart for real-time trading data and today's change.
Esperion Therapeutics Inc - Asset Composition Analysis
Esperion Therapeutics Inc Total Assets Breakdown (December 2024)
Esperion Therapeutics Inc total assets breakdown as of December 2024. Esperion Therapeutics Inc's total assets of $364.02 Million consist of 98.3% current assets and 1.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 42.1% |
| Accounts Receivable | $80.14 Million | 23.3% |
| Inventory | $94.49 Million | 27.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $56.00K | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1999–2024)
This chart illustrates how Esperion Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore ESPR working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Esperion Therapeutics Inc's current assets represent 98.3% of total assets in 2024, an increase from 75.6% in 1999.
- Cash Position: Cash and equivalents constituted 42.1% of total assets in 2024, down from 73.8% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1999.
- Asset Diversification: The largest asset category is inventory at 27.5% of total assets.
Esperion Therapeutics Inc Competitors by Total Assets
Key competitors of Esperion Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.44 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥2.54 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥25.73 Billion |
Esperion Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.00 | 1.85 | 3.68 |
| Quick Ratio | 0.61 | 1.37 | 3.51 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.43 Million | $141.68 Million | $251.83 Million |
Esperion Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Esperion Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 98.42 |
| Latest Market Cap to Assets Ratio | 2.11 |
| Asset Growth Rate (YoY) | 67.1% |
| Total Assets | $343.82 Million |
| Market Capitalization | $726.75 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Esperion Therapeutics Inc's assets at a significant premium (2.11x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Esperion Therapeutics Inc's assets grew by 67.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Esperion Therapeutics Inc (1999–2024)
The table below shows the annual total assets of Esperion Therapeutics Inc from 1999 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $343.82 Million | +67.07% |
| 2023-12-31 | $205.80 Million | -17.00% |
| 2022-12-31 | $247.94 Million | -35.02% |
| 2021-12-31 | $381.59 Million | +8.02% |
| 2020-12-31 | $353.26 Million | +64.73% |
| 2019-12-31 | $214.45 Million | +49.49% |
| 2018-12-31 | $143.45 Million | -48.37% |
| 2017-12-31 | $277.83 Million | +13.30% |
| 2016-12-31 | $245.21 Million | -17.04% |
| 2015-12-31 | $295.57 Million | +106.20% |
| 2014-12-31 | $143.34 Million | +83.08% |
| 2013-12-31 | $78.29 Million | +970.69% |
| 2012-12-31 | $7.31 Million | +235.47% |
| 2011-12-31 | $2.18 Million | -95.76% |
| 2002-12-31 | $51.41 Million | -34.38% |
| 2001-12-31 | $78.34 Million | +0.59% |
| 2000-12-31 | $77.88 Million | +873.60% |
| 1999-12-31 | $8.00 Million | -- |
About Esperion Therapeutics Inc
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary h… Read more